COSM News

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit

Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance

Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories